|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
|
|
|
|
5.12.4 IMMUNOTHÉRAPIES - ESSAIS
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
|
5.2 PHARMA
|
|
|
New drug development: ‘It’s the ecosystem, stupid’ [STAT]
|
|
|
|
|
|
If we are going to identify solutions that truly benefit patients, we must begin by recognizing that drug development occurs in a vibrant but fragile environment made up of entrepreneurs, investors, academics, government, patients, and yes, companies large and small. You cannot fundamentally alter one, without affecting all the others.
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
|
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019 [EMA]
|
|
|
|
|
|
The CHMP recommended granting marketing authorisations for the generic medicine Azacitidine Accord (azacitidine), for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia, diseases in which the body produces large numbers of abnormal blood cells. The Committee recommended extensions of indication for Akynzeo, Cyramza, Darzalex, Dificlir, Erleada, Sirturo, Stelara and Vyndaqel.
|
|
|
|
|
|
|
5.6.7 ESMO - IMMUNOTHÉRAPIES
|
|
|
|
|
5.6.7.1 ESMO-IMMUNOTHÉRAPIES-PEMBROLIZUMAB
|
|
|
|
|
5.7.2 SABCS-DIVERS
|
|
|
|
|
5.7.4 SABCS-ESSAIS
|
|
|
|
|
5.7.5 SABCS-BIOPSIES LIQUIDES
|
|
|
|
|
|
|
Liquid biopsy may predict breast cancer recurrence [UPI]
|
|
|
|
|
|
In study results expected for presentation Friday at the 2019 San Antonio Breast Cancer Symposium, researchers used a liquid biopsy -- FoundationOne Liquid, manufactured by a company called Foundation Medicine -- that detects circulating tumor DNA, or ctDNA, in a blood test to predict cancer recurrence.
|
|
|
|
|
|
|
5.7.6 SABCS-THS
|
|
|
|
|
|
5.7.7-SABCS-BIOMARQUEURS
|
|
|
|
|
6.10 POLITIQUES
|
|
|
Tory landslide election victory sets U.K. on path to Brexit [Fierce Biotech]
|
|
|
|
|
|
“The Prime Minister’s Brexit deal includes an important commitment to exploring close cooperation on medicine regulation. Achieving this will be important in prioritizing patients and public health as well as the future of the UK life sciences sector,” ABPI Chief Executive Mike Thompson said in a statement.
|
|
|
|
|
|
|
|
6.6 PUBLICATIONS
|
|
|